TCG Crossover (TCGX) is a science-driven healthcare investment firm that backs both private and public biotechnology companies globally. Their core thesis states that hard science drives fiscal returns, deploying capital into novel pre-IPO and public therapeutics addressing high unmet medical needs like advanced oncology. What makes TCGX unique is its specialized position as a dedicated crossover vehicle born out of The Column Group ecosystem, which provides companies with an elite, molecular-level technical network capable of guiding clinical assets straight through complex big-pharma M&A or public market listings.